EGFR and lung carcinoma: A combination of EAI045 and cetuximab is effective in mouse models of lung cancer driven by EGFR (L858R/T790M) and by EGFR (L858R/T790M/C797S) mutants.95 Moreover, Shen et al. designed and synthesized a series of 5-methylpyrimidopyridone derivatives as EGFR (L858R/T790M/C797S) inhibitors.96,97 The representative compound 8r-B inhibited EGFR (L858R/T790M/C797S) mutant with an IC50 of 27.5 nM.97 Further PK-oriented optimization of 8r-B is ongoing.